Top-News
Biotechnologie USA

Novavax News

Aktie
WKN:  A2PKMZ ISIN:  US6700024010 US-Symbol:  NVAX
11,99 €
+0,174 €
+1,47%
12:28:02 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
100,90 Mio.
Marktkapitalisierung *
1,19 Mrd. €
Streubesitz
37,03%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 07.11.2023

Unternehmensmeldungen

22.02.21 - GlobeNewswire
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a ...
18.02.21 - GlobeNewswire
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-​income countries ...
16.02.21 - GlobeNewswire
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government
04.02.21 - GlobeNewswire
Novavax und die Regierung der Schweiz geben eine Grundsatzvereinbarung zur Bereitstellung des COVID-19-Impfstoffes bekannt
Die Schweiz wird sechs Millionen Dosen des Impfstoffkandidaten NVX-CoV2373 von Novavax kaufen
04.02.21 - GlobeNewswire
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a ...
04.02.21 - GlobeNewswire
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
Switzerland to purchase six million doses of the Novavax vaccine candidate, NVX-CoV2373
28.01.21 - GlobeNewswire
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants
15.01.21 - GlobeNewswire
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-​stage biotechnology company developing next-​generation vaccines for serious ...
08.01.21 - GlobeNewswire
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
Advance Purchase Agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate Initial doses expected to be delivered as early as mid-2021 ...
28.12.20 - GlobeNewswire
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
PREVENT-19 will assess the efficacy, safety and immunogenicity of NVX-CoV2373 in the prevention of COVID-19 Trial to enroll up to 30,000 volunteers across approximately 115 ...
17.12.20 - GlobeNewswire
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
Advance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate
09.12.20 - GlobeNewswire
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
GAITHERSBURG, Md., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-​stage biotechnology company developing next-​generation vaccines for serious ...
30.11.20 - GlobeNewswire
Novavax Announces COVID-19 Vaccine Clinical Development Progress
Pivotal Phase 3 trial in United Kingdom completes enrollment Phase 2b efficacy trial in South Africa completes enrollment U.S./Mexico Phase 3 trial expected to begin in the coming ...
10.11.20 - GlobeNewswire
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
Novavax to host live Q&A due to technical difficulties during quarterly call
09.11.20 - GlobeNewswire
Novavax Reports Third Quarter 2020 Financial and Operational Results
Advanced clinical development of NVX ‑ CoV2373 with initiation of first Phase 3 trial to evaluate efficacy, safety and immunogenicity U.K. Phase 3 interim data expected as soon as ...
09.11.20 - GlobeNewswire
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
Covino brings global biopharmaceutical finance experience to Novavax John Trizzino , Chief Business Officer, takes on additional role as Chief Commercial Officer Filip Dubovsky, ...
09.11.20 - GlobeNewswire
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-​stage biotechnology company developing next-​generation vaccines for serious ...
04.11.20 - GlobeNewswire
Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
Heads of Terms signed to acquire 40 million doses of NVX-CoV2373
03.11.20 - GlobeNewswire
Novavax Appoints Biopharmaceutical Industry Veteran Gregg Alton to Board of Directors
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-​stage biotechnology company developing next-​generation vaccines for serious ...
03.11.20 - GlobeNewswire
Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-​generation vaccines for serious ...

Newssuche

Videos

newspaper
27.06.24 -3,89%
Technical Trading: 10yr T-Notes Long Chance
10yr T-Notes Long Typ: Turbo Open End WKN: JL04UJ Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »